GOSS: Announces Topline Results for Phase 3 PROSERA Trial -- LEVI & KORSINSKY, LLP

Core Insights - Gossamer Bio, Inc. experienced a significant decline of over 60% in its stock value following the Phase 3 PROSERA trial results for seralutinib, which missed its primary endpoint [1] - The company's CEO had previously set expectations for positive results in February 2026, indicating optimism about the trial's outcome [1] - The trial's statistical plan required a significance level of alpha = 0.025, which was not disclosed to investors, leading to a gap between management's guidance and the actual statistical requirements [1] Company Performance - The actual p-value from the PROSERA trial was reported at 0.032, which, while passing the conventional 0.05 threshold, did not meet the more stringent 0.025 requirement [1] - The lack of disclosure regarding the heightened statistical threshold created an elevated risk for investors who relied on the company's forward-looking statements [1] Investor Impact - Shareholders who invested in Gossamer Bio and incurred losses are encouraged to seek legal advice regarding their rights [1] - The investigation focuses on the discrepancy between the company's optimistic guidance and the undisclosed statistical hurdles that contributed to the trial's failure [1]